24/7 Patient Assistance: 760-405-8205

Henry Koon , MD

Medical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma

Hospitals & Clinics

  • Bio & Insurance Information

    Dr. Henry Koon is a medical oncologist from Cleveland, Ohio and he works at several hospitals in the area, such as University Hospitals Cleveland Medical Center. He did his Medical Schooling from University of Mississippi School of Medicine and Residency in Internal Medicine from University of Mississippi Medical Center. The doctor is certified in Medical Oncology from American Board of Internal Medicine and has an experience of more than 20 years.



  • Education & Training

    dept_icon

    University of Mississippi School of Medicine

    Medical School

    dept_icon

    University of Mississippi Medical Center

    Residency

  • Board Certifications

    American Board of Internal Medicine - Oncology

  • Publications & Memberships

    Dr. Henry Koon has contributed to 3 publications.

    A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).

    Kalinsky, K.,Lee, S.,Rubin, K. M.,Lawrence, D. P.,Iafrarte, A. J.,Borger, D. R.,Margolin, K. A.,Leitao, M. M.,Tarhini, A. A.,Koon, H. B.,Pecora, A. L.,Jaslowski, A. J....; Cancer. 2017 Mar 24.

    See more >>

    Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.

    von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Conrad EU 3rd, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM 3rd, Koon H, Mayerson J, McCarter M, McGarr...; J Natl Compr Canc Netw. 2016 Jun.

    See more >>

    Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma.

    Amin A, Lawson DH, Salama AK, Koon HB, Guthrie T Jr, Thomas SS, O'Day SJ, Shaheen MF, Zhang B, Francis S, Hodi FS; J Immunother Cancer. 2016.

    See more >>